TRIQUILAR 50 µg/1 tableta+ 30 µg/1 tableta+ 75 µg/1 tableta+ 40 µg/1 tableta+ 125 µg/1 tableta+ 30 µg/1 tableta obložena tableta Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

triquilar 50 µg/1 tableta+ 30 µg/1 tableta+ 75 µg/1 tableta+ 40 µg/1 tableta+ 125 µg/1 tableta+ 30 µg/1 tableta obložena tableta

bayer d.o.o. sarajevo - etinilestradiol, levonorgestrel - obložena tableta - 50 µg/1 tableta+ 30 µg/1 tableta+ 75 µg/1 tableta+ 40 µg/1 tableta+ 125 µg/1 tableta+ 30 µg/1 tableta - 1 obložena tableta sadrži: 50 mcg levonorgestre + etinilestradiol 30 mcg (crvenosmeđa) 75 mcg levonorgestre + etinilestradiol 40 mcg (bijela) 125 mcg levonorgestre + etinilestradiol 30 mcg (tamnožuta)

Insuman Европейский союз - хорватский - EMA (European Medicines Agency)

insuman

sanofi-aventis deutschland gmbh - insulin human - Šećerna bolest - lijekovi koji se koriste u dijabetesu - diabetes mellitus gdje je potrebno liječenje inzulinom. insuman rapid je pogodan za liječenje hiperglikemijsku komu i ketoacidoza, kao i za postizanje unaprijed, intra - i postoperativna stabilizacija u bolesnika sa šećernom bolešću.

Blincyto Европейский союз - хорватский - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.